Post Marketing Surveillance Study to Observe Safety and Efficacy of Inlyta

Trial Profile

Post Marketing Surveillance Study to Observe Safety and Efficacy of Inlyta

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 10 Apr 2018

At a glance

  • Drugs Axitinib (Primary)
  • Indications Renal cell carcinoma
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 04 Apr 2018 Planned End Date changed from 21 Aug 2018 to 20 Apr 2022.
    • 04 Apr 2018 Planned primary completion date changed from 21 Aug 2018 to 20 Apr 2022.
    • 04 Apr 2018 Planned initiation date changed from 31 Mar 2018 to 30 Apr 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top